Cochlear (ASX:COH) will continue to operate under a duty-free arrangement with the US as it awaits clarity on recent trade developments, the maker of hearing implants said in a Tuesday filing with the Australian bourse.
Cochlear is currently under the Harmonized Tariff Schedule of the US that provides duty-free importation on a range of products into the US, including hearing implants, per the filing.
The company said it will "continue to actively monitor and engage in the evolving global landscape" in line with the imposition of a 10% tariff on exports to the US from Australia.